Stockreport

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Humacyte, Inc.  (HUMA) 
PDF Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcomi [Read more]